Stock Market Reviews

AXSM (Axsome Therapeutics, Inc.) News

Get the latest news, insights, and market updates on AXSM (Axsome Therapeutics, Inc.). Explore the news page 8 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Axsome: Q3 Earnings Snapshot
  NEW YORK (AP) — Axsome Therapeutics Inc. AXSM) on Monday reported a loss of $47.2 million in its third quarter. The New York-based company said it had a loss of 94 cents per share.
  Nov 3, 2025 - $AXSM
• uniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
  uniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Oct 28, 2025 - $AXSM
• Axsome Therapeutics (AXSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Oct 27, 2025 - $AXSM
• Axsome Therapeutics to Participate in Upcoming Investor Conferences
  NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in November: 2025 Truist Securities BioPharma Symposium Fireside Chat: Thursday, November 6, 2025, at 9:50 a.m. ET in New York, NY Guggenheim 2nd Annual Healthcare Innovation ConferenceFireside Chat: Monday, November 10,
  Oct 22, 2025 - $AXSM
• Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
  NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is recognizing Mental Illness Awareness Week (MIAW) alongside the national mental health advocacy community including the National Alliance on Mental Illness (NAMI). This year’s theme for MIAW is “Building Community: Supporting Mental Well-being Together,” to highlight the importance of m
  Oct 9, 2025 - $AXSM
• Axsome Therapeutics (AXSM): Exploring Valuation After Recent Share Price Stability
  Axsome Therapeutics (AXSM) has seen its stock move slightly over the past week, even as broader biotech markets have been mixed. Investors appear to be weighing recent performance trends and the company’s value proposition as sector volatility continues. See our latest analysis for Axsome Therapeutics. Axsome's recent share price dips have barely made a dent in its impressive rally this year. The company has achieved a 35.95% year-to-date share price return and a strong 42.1% total...
  Oct 9, 2025 - $AXSM
• Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
  NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the third quarter of 2025 on Monday, November 3, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participat
  Oct 7, 2025 - $AXSM
• Piper Sandler Maintains Overweight on Axsome (AXSM), Sees Growth in AD-Agitation
  Axsome Therapeutics Inc. (NASDAQ:AXSM) ranks among the best biotech stocks to buy. Following a recent discussion with the senior management at Axsome Therapeutics Inc. (NASDAQ:AXSM), Piper Sandler reiterated its Overweight rating on the company and set a price target of $148 on its shares. The firm learned about Axsome’s commercial support methods for Auvelity in […]
  Oct 2, 2025 - $AXSM
• Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
  Both should have significant catalysts by the end of the decade.
  Sep 30, 2025 - $AXSM
• Can Auvelity Drive Axsome's Growth Through the Rest of 2025?
  AXSM's Auvelity drives 82% sales growth in the first half of 2025, with label expansion studies and other marketed products bolstering its CNS drug portfolio.
  Sep 30, 2025 - $AXSM